Novartis AG Bone Marrow Cancer Drug Wows In Late-Stage Study

An experimental drug from Novartis to treat a type of bone marrow cancer met its primary goal in a late-stage study, the Swiss drugmaker said on Friday. A Phase III trial found the drug, dubbed LBH589 when combined with bortezomib and dexamethasone, significantly extended progression-free survival in patients with relapsed or relapsed and refractory multiple myeloma compared to bortezomib and dexamethasone alone. Multiple myeloma is a cancer that starts in plasma cells in bone marrow and disrupts the production of normal blood cells.

Help employers find you! Check out all the jobs and post your resume.